Vercise DBS Systems
Boston Scientific Corp · Decision date Oct 15, 2026
What did the FDA approve?
The FDA database records decision APPR on 2026-10-15 for P150031/S100, a Special (Immediate Track) supplement from Boston Scientific Corp. The source statement describes approval for additional guidance in use of a Clinician Programmer feature covering the Implantable Pulse Generator battery recharge interval and battery longevity estimates for non-rechargeable IPGs. The listed reason is a labeling change; the device category is an implanted electrical stimulator for parkinsonian symptoms, product code NHL, in neurology.
The identifier P150031/S100 ties this action to the existing P150031 approval as a supplement, not a new approval of the whole Vercise DBS system. The statement does not specify the revised label wording, which IPG models are covered, the programming steps involved, or evidence behind the estimates; its stated purpose is not independent proof of safety or clinical effectiveness. No clinical use is implied.
FDA approval order statement
approval for providing additional guidance in the use of Clinician Programmer feature for Implantable Pulse Generator (IPG) battery recharge interval and non-rechargeable IPG battery longevity estimates.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Neurology
- Decision date
- Oct 15, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150031/S100
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- Decision code
- APPR
- Decision date
- Oct 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150031 · Original PMA
VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM
P150031/S084 · Related supplement
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM
P150031/S100 received
Application receipt date recorded by FDA.
P150031/S098 · Related supplement
Vercise Genus DBS Systems; Vercise Gevia DBS Systems
P150031/S100 · FDA decision
Special (Immediate Track)
P150031/S102 · Related supplement
Vercise Deep Brain Stimulation (DBS) Systems
Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA approval | Dec 8, 2017 | FDA | |
VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEMP150031/S084 | Boston Scientific Corp | PMA supplement | Sep 13, 2026 | FDA |
| Boston Scientific Corp | PMA supplement | Sep 22, 2026 | FDA | |
Vercise Deep Brain Stimulation (DBS) SystemsP150031/S102 | Boston Scientific Corp | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P150031/S100
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
